HLB Pep Co., Ltd. (KOSDAQ:196300)

Market Cap	95.81B
Revenue (ttm)	6.23B
Net Income (ttm)	-6.79B
Shares Out	9.29M
EPS (ttm)	-1,135.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	72,369
Average Volume	49,350
Open	10,300
Previous Close	10,000
Day's Range	10,130 - 10,850
52-Week Range	5,580 - 17,270
Beta	0.52
RSI	59.23
Earnings Date	n/a

About HLB Pep

HLB Pep Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It offers GMP, generic, custom, and catalog peptides, as well as offers other services. The company develops AGM-130, which is in Phase I for the treatment of triple negative breast cancer. In addition, its pre-clinical products include AGM-331 targeted for anti-cancer therapy; AGM-380 indicated for the treatment of viral infection; and AGM-290 indicated for the treatment of infections ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 196300

Financial Performance

In 2024, Anygen's revenue was 6.23 billion, an increase of 11.02% compared to the previous year's 5.61 billion. Losses were -6.79 billion, -25.18% less than in 2023.